Crux Biomedical (Menlo Park, CA) a clinical-stage is developing an implantable vascular device that offers potential improvement over existing inferior vena cava filter filters for treating and preventing pulmonary embolisms, closed an $8M Series B financing. Participants include Alloy Ventures and 1963 inventor of the balloon embolectomy catheter Thomas Fogarty.